Personal information

Other IDs

ResearcherID: E-1331-2012

Keywords

CLL pathogenesis

Countries

Czech Republic

Activities

Collapse all

Employment (5)

Středoevropský technologický institut: Brno, CZ

2017-12-01 to present | Researcher (Medical Genomics)
Employment
Source: Self-asserted source
Veronika Navrkalova

Fakultní Nemocnice Brno: Brno, CZ

2017-11-01 to present | Researcher (IHOK - CMBGT)
Employment
Source: Self-asserted source
Veronika Navrkalova

Středoevropský technologický institut: Brno, CZ

2011 to 2016 | PhD student/Researcher (Medical Genomics)
Employment
Source: Self-asserted source
Veronika Navrkalova

Fakultní Nemocnice Brno: Brno, CZ

2009 to 2016 | PhD student/Researcher (IHOK - CMBGT)
Employment
Source: Self-asserted source
Veronika Navrkalova

Státní veterinární ústav Jihlava: Jihlava, CZ

2008 to 2009 | odborný pracovník (Oddělení virologie a sérologie - laboratoř molekulární biologie)
Employment
Source: Self-asserted source
Veronika Navrkalova

Education and qualifications (2)

Masaryk University: Brno, CZ

2009 to 2014 | Ph.D. (Faculty of Medicine - Oncology)
Education
Source: Self-asserted source
Veronika Navrkalova

Palacký University, Olomouc: Olomouc, CZ

2003 to 2008 | Mgr. (Faculty of Science - Molecular and cell biology)
Education
Source: Self-asserted source
Veronika Navrkalova

Works (20)

Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single‐cell RNA sequencing

Molecular Oncology
2024-05-21 | Journal article
DOI: 10.1002/1878-0261.13663
Contributors: Terezia Kurucova; Kamila Reblova; Pavlina Janovska; Jakub Pawel Porc; Veronika Navrkalova; Sarka Pavlova; Jitka Malcikova; Karla Plevova; Boris Tichy; Michael Doubek et al.
Source: check_circle
Crossref

Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment‐naïve CLL patients

British Journal of Haematology
2024-01 | Journal article
DOI: 10.1111/bjh.19191
Contributors: Veronika Navrkalova; Karla Plevova; Lenka Radova; Jakub Porc; Karol Pal; Jitka Malcikova; Sarka Pavlova; Michael Doubek; Anna Panovska; Jana Kotaskova et al.
Source: check_circle
Crossref

Very rare near‐haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR‐T therapy in 19‐year‐old male patient

Clinical Case Reports
2022-03 | Journal article
DOI: 10.1002/ccr3.5545
Contributors: Tomas Arpas; Hana Jelinkova; Stepan Hrabovsky; Martina Orsulova; Zuzana Vrzalova; Veronika Navrkalova; Eva Brhelova; Lenka Bryjova; Alena Bulikova; Eva Ondrouskova et al.
Source: check_circle
Crossref

LYmphoid NeXt-Generation Sequencing (LYNX) Panel

The Journal of Molecular Diagnostics
2021-08 | Journal article
DOI: 10.1016/j.jmoldx.2021.05.007
Contributors: Veronika Navrkalova; Karla Plevova; Jakub Hynst; Karol Pal; Andrea Mareckova; Tomas Reigl; Hana Jelinkova; Zuzana Vrzalova; Kamila Stranska; Sarka Pavlova et al.
Source: check_circle
Crossref

Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application

PeerJ
2021-03-31 | Journal article
DOI: 10.7717/peerj.10897
Contributors: Jakub Hynst; Veronika Navrkalova; Karol Pal; Sarka Pospisilova
Source: check_circle
Crossref

Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.

British journal of haematology
2017-09 | Journal article
DOI: 10.1111/bjh.14176
PMID: 27470445
Contributors: Kantorova B; Malcikova J; Brazdilova K; Borsky M; Plevova K; Smardova J; Radova L; Tom N; Trbusek M; Diviskova E et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Leukemia
2017-07 | Journal article
DOI: 10.1038/leu.2016.359
PMID: 27890934
Contributors: Young E; Noerenberg D; Mansouri L; Ljungström V; Frick M; Sutton LA; Blakemore SJ; Galan-Sousa J; Plevova K; Baliakas P et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

Ability to downregulate the level of cyclin-dependent kinase inhibitor p27(Kip1) after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.

Leukemia & lymphoma
2017-01 | Journal article
DOI: 10.1080/10428194.2016.1187276
PMID: 27268868
Contributors: Raskova Kafkova L; Navrkalova V; Jarosova M; Loja T; Chovancova J; Kucerova J; Kriegova E; Prochazka V; Novak Z; Simkova D et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.

Haematologica
2016-09 | Journal article
DOI: 10.3324/haematol.2016.142968
PMID: 27479817
PMC: PMC5060033
Contributors: Navrkalova V; Young E; Baliakas P; Radova L; Sutton LA; Plevova K; Mansouri L; Ljungström V; Ntoufa S; Davis Z et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

[Molecular Prognostic Markers and Their Clinical Relevance in Chronic Lymphocytic Leukemia].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
2015 | Journal article
PMID: 26489496
Contributors: Navrkalová V; Kantorová B; Jarošová M; Pospíšilová Š
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.

Cell death & disease
2015 | Journal article
DOI: 10.1038/cddis.2015.223
PMID: 26247737
PMC: PMC4558513
Contributors: te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients.

Haematologica
2015-08 | Journal article
DOI: 10.3324/haematol.2015.130260
PMID: 26314081
PMC: PMC5004413
Contributors: Navrkalova V; Kafkova LR; Divoky V; Pospisilova S
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

The impact of SF3B1 mutations in CLL on the DNA-damage response.

Leukemia
2015-05 | Journal article
DOI: 10.1038/leu.2014.318
PMID: 25371178
Contributors: Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.

Haematologica
2015-03 | Journal article
DOI: 10.3324/haematol.2014.109777
PMID: 25480502
PMC: PMC4349276
Contributors: Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Leukemia
2015-02 | Journal article
DOI: 10.1038/leu.2014.196
PMID: 24943832
Contributors: Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.

Experimental hematology
2014-10 | Journal article
DOI: 10.1016/j.exphem.2014.06.003
PMID: 24970561
Contributors: Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia.

Carcinogenesis
2014-05 | Journal article
DOI: 10.1093/carcin/bgt396
PMID: 24306027
PMC: PMC4004199
Contributors: Kminkova J; Mraz M; Zaprazna K; Navrkalova V; Tichy B; Plevova K; Malcikova J; Cerna K; Rausch T; Benes V et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.

Leukemia & lymphoma
2013-08 | Journal article
DOI: 10.3109/10428194.2013.796056
PMID: 23808769
Contributors: Navrkalova V; Sebejova L; Zemanova J; Jaskova Z; Trbusek M
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Haematologica
2013-07 | Journal article
DOI: 10.3324/haematol.2012.081620
PMID: 23585524
PMC: PMC3696617
Contributors: Navrkalova V; Sebejova L; Zemanova J; Kminkova J; Kubesova B; Malcikova J; Mraz M; Smardova J; Pavlova S; Doubek M et al.
Source: Self-asserted source
Veronika Navrkalova via Europe PubMed Central

Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.

Leuk Lymphoma
2012 | Journal article
DOI: 10.3109/10428194.2012.658794
Contributors: Doubek, M.; Trbušek, M.; Malčíková, J.; Brychtová, Y.; Smardová, J.; Lochmanová, J.; Panovská, A.; Francová, H. S.; Mráz, M.; Tichý, B. et al.
Source: Self-asserted source
Veronika Navrkalova via ResearcherID
How many people are using ORCID?